Ramoplanin
Also known as: A-16686, A-77041, MDL 62,198, Ramoplanin, Ramoplanose
Source Ramoplanin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Ramoplanin is a cyclic lipoglycodepsipeptide antibiotic active against Gram‑positive bacteria, investigated for oral treatment of Clostridioides difficile infection and other resistant infections.
Mechanism of Action
Binds to lipid II and blocks transglycosylation, inhibiting bacterial cell‑wall peptidoglycan synthesis
Routes of Administration
Goals & Uses
- Eradication of VRE intestinal colonizationAntimicrobial / DecolonizationModerate
- Clostridioides difficile infectionInfectionModerate
- Prevention of bacteremia in immunocompromised patients colonized with VREAntimicrobial / ProphylaxisLow
- Vancomycin‑resistant Enterococci (VRE)InfectionModerate
- Treatment of Clostridioides difficile infectionAntimicrobialModerate
- Activity against MRSAAntimicrobialLow
- Methicillin‑resistant Staphylococcus aureus (MRSA)InfectionModerate
Contraindications
- Hypersensitivity to ramoplaninAllergyHigh
- Severe renal impairmentOrganModerateKidney function concerns
- Known hypersensitivity to ramoplanin or glycodepsipeptidesAllergyHigh
Adverse Effects
- RashDermatologicUncommonSkin eruption or discoloration
- Injection site reactions (if parenteral)LocalUnknown
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalUncommonForceful expulsion of stomach contents
- DiarrheaGastrointestinalCommonLoose or frequent stools
- Abdominal painGastrointestinalUncommonPain or discomfort in the abdomen
Drug Interactions
- Antacids (aluminum/magnesium)Moderate
- Oral anticoagulants (e.g., warfarin)Low
- Broad‑spectrum antibioticsLow
Population Constraints
- Severe gastrointestinal mucosal damageGastrointestinalRelative
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization.
- United StatesInvestigationalPhase II oral trials for C. difficile; not FDA‑approved.
- United KingdomUnapprovedNo licensing; used only in research settings.
Not approved by FDA, EMA or MHRA; used only in clinical trials and limited compassionate‑use programs.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Ramoplanin?
Ramoplanin is a cyclic lipoglycodepsipeptide antibiotic active against Gram‑positive bacteria, investigated for oral treatment of Clostridioides difficile infection and other resistant infections.
What is Ramoplanin used for?
Ramoplanin is educationally associated with: Eradication of VRE intestinal colonization, Clostridioides difficile infection, Prevention of bacteremia in immunocompromised patients colonized with VRE, Vancomycin‑resistant Enterococci (VRE), Treatment of Clostridioides difficile infection, Activity against MRSA, Methicillin‑resistant Staphylococcus aureus (MRSA). Educational only — not medical advice.
How is Ramoplanin administered?
Recorded routes of administration: Oral, Topical.
What are the potential side effects of Ramoplanin?
Reported adverse effects include: Rash, Injection site reactions (if parenteral), Nausea, Vomiting, Diarrhea, Abdominal pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Ramoplanin?
Recorded contraindications: Hypersensitivity to ramoplanin, Severe renal impairment, Known hypersensitivity to ramoplanin or glycodepsipeptides. Consult a qualified clinician before use.